CoChat
Sign Up
Cited by 76

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Deciphering the Molecular Profile of Plaques, Memory Decline and Neuron Loss in Two Mouse Models for Alzheimer’s Disease by Deep Sequencing

Bouter, Yvonne, Kacprowski, Tim, Weissmann, Robert, Dietrich, Katharina, Borgers, Henning, Brauß, Andreas, Sperling, Christian, Wirths, Oliver, Albrecht, Mario, Jensen, Lars R., Kuss, Andreas W., Bayer, Thomas A.·2014·Frontiers in Aging Neuroscience
DOI 10.3389/fnagi.2014.00075PMC PMC3997018
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2014.00075

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 100

  1. Akiyama, 2000, Inflammation and Alzheimer’s disease, Neurobiol. Aging, 21, 383, 10.1016/S0197-4580(00)00124-X · DOI · Paper page
  2. Altar, 2009, Target identification for CNS diseases by transcriptional profiling, Neuropsychopharmacology, 34, 18, 10.1038/npp.2008.172 · DOI
  3. 2012, 2012 Alzheimer’s disease facts and figures, Alzheimers Dement., 8, 131, 10.1016/j.jalz.2012.02.001 · DOI
  4. Anders, 2010, Differential expression analysis for sequence count data, Genome Biol., 11, R106, 10.1186/gb-2010-11-10-r106 · DOI · Paper page
  5. Arnaud, 2006, It may take inflammation, phosphorylation and ubiquitination to ‘tangle’ in Alzheimer’s disease, Neurodegener. Dis., 3, 313, 10.1159/000095638 · DOI
  6. Ashburner, 2000, Gene ontology: tool for the unification of biology. The gene ontology consortium, Nat. Genet., 25, 25, 10.1038/75556 · DOI · Paper page
  7. Bast, 2003, Dorsal hippocampus and classical fear conditioning to tone and context in rats: effects of local NMDA-receptor blockade and stimulation, Hippocampus, 13, 657, 10.1002/hipo.10115 · DOI
  8. Benilova, 2012, The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes, Nat. Neurosci., 15, 349, 10.1038/nn.3028 · DOI · Paper page
  9. Bertram, 2001, Dancing in the dark? The status of late-onsetalzheimer’s disease genetics, J. Mol. Neurosci., 17, 127, 10.1385/JMN:17:2:127 · DOI
  10. Blennow, 2006, Alzheimer’s disease, Lancet, 368, 387, 10.1016/S0140-6736(06)69113-7 · DOI · Paper page
  11. Bossers, 2010, Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer’s disease, Brain, 133, 3699, 10.1093/brain/awq258 · DOI · Paper page
  12. Breyhan, 2009, APP/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy, Acta Neuropathol., 117, 677, 10.1007/s00401-009-0539-7 · DOI · Paper page
  13. Carrette, 2003, A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer’s disease, Proteomics, 3, 1486, 10.1002/pmic.200300470 · DOI
  14. Casas, 2004, Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model, Am. J. Pathol., 165, 1289, 10.1016/S0002-9440(10)63388-3 · DOI · Paper page
  15. Chen, 2000, A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer’s disease, Nature, 408, 975, 10.1038/35050103 · DOI · Paper page
  16. Cheng, 2013, The detection of microRNA associated with Alzheimer’s disease in biological fluids using next-generation sequencing technologies, Front. Genet., 4, 150, 10.3389/fgene.2013.00150 · DOI
  17. Choi, 2013, MicroRNA profiling in the mouse hypothalamus reveals oxytocin-regulating microRNA, J. Neurochem., 126, 331, 10.1111/jnc.12308 · DOI
  18. Christensen, 2010, Intracellular Aß triggers neuron loss in the cholinergic system of the APP/PS1KI mouse model of Alzheimer’s disease, Neurobiol. Aging, 31, 1153, 10.1016/j.neurobiolaging.2008.07.022 · DOI · Paper page
  19. Cocco, 2010, Distribution of VGF peptides in the human cortex and their selective changes in Parkinson’s and Alzheimer’s diseases, J. Anat, 217, 683, 10.1111/j.1469-7580.2010.01309.x · DOI
  20. Couillard-Despres, 2005, Doublecortin expression levels in adult brain reflect neurogenesis, Eur. J. Neurosci., 21, 1, 10.1111/j.1460-9568.2004.03813.x · DOI
  21. Courtney, 2010, Transcriptome profiling in neurodegenerative disease, J. Neurosci. Methods, 193, 189, 10.1016/j.jneumeth.2010.08.018 · DOI
  22. Cruz, 2004, Cdk5 deregulation in the pathogenesis of Alzheimer’s disease, Trends Mol. Med., 10, 452, 10.1016/j.molmed.2004.07.001 · DOI · Paper page
  23. Delacourte, 1990, General and dramatic glial reaction in Alzheimer brains, Neurology, 40, 33, 10.1212/WNL.40.1.33 · DOI
  24. Dickey, 2003, Selectively reduced expression of synaptic plasticity-related genes in amyloid precursor protein + presenilin-1 transgenic mice, J. Neurosci., 23, 5219, 10.1523/JNEUROSCI.23-12-05219.2003 · DOI · Paper page
  25. España, 2010, Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer’s disease transgenic mice, Biol. Psychiatry, 67, 513, 10.1016/j.biopsych.2009.06.015 · DOI
  26. Farris, 2003, Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo, Proc. Natl. Acad. Sci. U.S.A., 100, 4162, 10.1073/pnas.0230450100 · DOI
  27. George, 2010, A serial analysis of gene expression profile of the Alzheimer’s disease Tg2576 mouse model, Neurotox. Res., 17, 360, 10.1007/s12640-009-9112-3 · DOI
  28. Glaser, 2006, Multiple epigenetic maintenance factors implicated by the loss of Mll2 in mouse development, Development, 133, 1423, 10.1242/dev.02302 · DOI
  29. Haughey, 2002a, Disruption of neurogenesis in the subventricular zone of adult mice, and in human cortical neuronal precursor cells in culture, by amyloid beta-peptide: implications for the pathogenesis of Alzheimer’s disease, Neuromolecular Med., 1, 125, 10.1385/NMM:1:2:125 · DOI · Paper page
  30. Haughey, 2002b, Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer’s disease, J. Neurochem., 83, 1509, 10.1046/j.1471-4159.2002.01267.x · DOI · Paper page
  31. Haupt, 2012, Structural basis of β-amyloid-dependent synaptic dysfunctions, Angew. Chem. Int. Ed. Engl., 51, 1576, 10.1002/anie.201105638 · DOI
  32. Hillmann, 2012, No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer’s disease, Neurobiol. Aging, 33, .e39, 10.1016/j.neurobiolaging.2011.08.006 · DOI
  33. Hirokawa, 2010, Molecular motors in neurons: transport mechanisms and roles in brain function, development, and disease, Neuron, 68, 610, 10.1016/j.neuron.2010.09.039 · DOI · Paper page
  34. Hook, 2009, Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein, Biochem. Biophys. Res. Commun., 386, 284, 10.1016/j.bbrc.2009.05.131 · DOI
  35. Jaffrey, 2002, Neuronal nitric-oxide synthase localization mediated by a ternary complex with synapsin and CAPON, Proc. Natl. Acad. Sci. U.S.A., 99, 3199, 10.1073/pnas.261705799 · DOI
  36. Jahn, 2011, Peptide fingerprinting of Alzheimer’s disease in cerebrospinal fluid: identification and prospective evaluation of new synaptic biomarkers, PLoS ONE, 6, e26540, 10.1371/journal.pone.0026540 · DOI
  37. Jawhar, 2011, Pyroglutamate amyloid-β (Aβ): a hatchet man in Alzheimer disease, J. Biol. Chem., 286, 38825, 10.1074/jbc.R111.288308 · DOI
  38. Jin, 2004, Increased hippocampal neurogenesis in Alzheimer’s disease, Proc. Natl. Acad. Sci. U.S.A., 101, 343, 10.1073/pnas.2634794100 · DOI · Paper page
  39. Kalinin, 2009, A PPARdelta agonist reduces amyloid burden and brain inflammation in a transgenic mouse model of Alzheimer’s disease, Curr. Alzheimer Res., 6, 431, 10.2174/156720509789207949 · DOI
  40. Kerimoglu, 2013, Histone-methyltransferase MLL2 (KMT2B) is required for memory formation in mice, J. Neurosci., 33, 3452, 10.1523/JNEUROSCI.3356-12.2013 · DOI
  41. Kishimoto, 2013, Early impairment in a water-finding test in a longitudinal study of the Tg2576 mouse model of Alzheimer’s disease, Brain Res., 1491, 117, 10.1016/j.brainres.2012.10.066 · DOI
  42. Klein, 2002, Abeta toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets, Neurochem. Int., 41, 345, 10.1016/S0197-0186(02)00050-5 · DOI
  43. Ko, 2004, Ubiquilin interacts with ubiquitylated proteins and proteasome through its ubiquitin-associated and ubiquitin-like domains, FEBS Lett, 566, 110, 10.1016/j.febslet.2004.04.031 · DOI
  44. Kondo, 2012, Motor protein KIF1A is essential for hippocampal synaptogenesis and learning enhancement in an enriched environment, Neuron, 73, 743, 10.1016/j.neuron.2011.12.020 · DOI
  45. Lambert, 2009, Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease, Nat. Genet., 41, 1094, 10.1038/ng.439 · DOI · Paper page
  46. Leskovjan, 2011, Increased brain iron coincides with early plaque formation in a mouse model of Alzheimer’s disease, Neuroimage, 55, 32, 10.1016/j.neuroimage.2010.11.073 · DOI
  47. Lesné, 2013, Brain amyloid-β oligomers in ageing and Alzheimer’s disease, Brain, 136, 1383, 10.1093/brain/awt062 · DOI
  48. Li, 2011, Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer’s disease?, Mol. Neurodegener., 6, 79, 10.1186/1750-1326-6-79 · DOI
  49. Lidström, 1998, Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer’s disease, Exp. Neurol., 154, 511, 10.1006/exnr.1998.6892 · DOI
  50. Lundberg, 2010, Defining the transcriptome and proteome in three functionally different human cell lines, Mol. Syst. Biol., 6, 450, 10.1038/msb.2010.106 · DOI · Paper page
  51. Masters, 1985, Amyloid plaque core protein in Alzheimer disease and Down syndrome, Proc. Natl. Acad. Sci. U.S.A., 82, 4245, 10.1073/pnas.82.12.4245 · DOI · Paper page
  52. McLean, 1999, Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease, Ann. Neurol., 46, 860, 10.1002/1531-8249(199912)46:6860::AID-ANA83.0.CO;2-M · DOI
  53. Medway, 2014, Review: the genetics of Alzheimer’s disease; putting flesh on the bones, Neuropathol. Appl. Neurobiol., 40, 97, 10.1111/nan.12101 · DOI
  54. Miller, 1993, Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer’s disease, Arch. Biochem. Biophys., 301, 41, 10.1006/abbi.1993.1112 · DOI · Paper page
  55. Miners, 2009, Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity, J. Neuropathol. Exp. Neurol., 68, 902, 10.1097/NEN.0b013e3181afe475 · DOI
  56. Moechars, 1999, Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain, J. Biol. Chem., 274, 6483, 10.1074/jbc.274.10.6483 · DOI · Paper page
  57. Moechars, 1996, Expression in brain of amyloid precursor protein mutated in the alpha-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice, EMBO J., 15, 1265, 10.1002/j.1460-2075.1996.tb00468.x · DOI · Paper page
  58. Morris, 1984, Developments of a water-maze procedure for studying spatial learning in the rat, J. Neurosci. Methods, 11, 47, 10.1016/0165-0270(84)90007-4 · DOI · Paper page
  59. Nagalakshmi, 2008, The transcriptional landscape of the yeast genome defined by RNA sequencing, Science, 320, 1344, 10.1126/science.1158441 · DOI · Paper page
  60. Nikolic, 1996, The cdk5/p35 kinase is essential for neurite outgrowth during neuronal differentiation, Genes Dev., 10, 816, 10.1101/gad.10.7.816 · DOI
  61. Nilselid, 2006, Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms, Neurochem. Int., 48, 718, 10.1016/j.neuint.2005.12.005 · DOI · Paper page
  62. Ohno, 2009, Failures to reconsolidate memory in a mouse model of Alzheimer’s disease, Neurobiol. Learn. Mem., 92, 455, 10.1016/j.nlm.2009.05.001 · DOI · Paper page
  63. Pfaffl, 2002, Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR, Nucleic Acids Res., 30, e36, 10.1093/nar/30.9.e36 · DOI
  64. Pham, 2010, Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins, FEBS J., 277, 3051, 10.1111/j.1742-4658.2010.07719.x · DOI · Paper page
  65. Prelli, 1988, Differences between vascular and plaque core amyloid in Alzheimer’s disease, J. Neurochem., 51, 648, 10.1111/j.1471-4159.1988.tb01087.x · DOI
  66. Price, 1999, Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease, Ann. Neurol., 45, 358, 10.1002/1531-8249(199903)45:3358::AID-ANA123.0.CO;2-X · DOI
  67. Qin, 2004, Regional alteration of synapsin I in the hippocampal formation of Alzheimer’s disease patients, Acta Neuropathol., 107, 209, 10.1007/s00401-003-0800-4 · DOI
  68. Rademakers, 2005, Association of cyclin-dependent kinase 5 and neuronal activators p35 and p39 complex in early-onsetalzheimer’s disease, Neurobiol. Aging, 26, 1145, 10.1016/j.neurobiolaging.2004.10.003 · DOI
  69. Roberts, 2012, The role of metallobiology and amyloid-β peptides in Alzheimer’s disease, J. Neurochem., 120, 149, 10.1111/j.1471-4159.2011.07500.x · DOI · Paper page
  70. Rogers, 1992, Complement activation by beta-amyloid in Alzheimer disease, Proc. Natl. Acad. Sci. U.S.A., 89, 10016, 10.1073/pnas.89.21.10016 · DOI · Paper page
  71. Roychaudhuri, 2009, Amyloid beta-protein assembly and Alzheimer disease, J. Biol. Chem., 284, 4749, 10.1074/jbc.R800036200 · DOI
  72. Schuur, 2011, Cathepsin D gene and the risk of Alzheimer’s disease: a population-based study and meta-analysis, Neurobiol. Aging, 32, 1607, 10.1016/j.neurobiolaging.2009.10.011 · DOI
  73. Selkoe, 1998, The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer’s disease, Trends Cell Biol., 8, 447, 10.1016/S0962-8924(98)01363-4 · DOI · Paper page
  74. Selkoe, 2011, Resolving controversies on the path to Alzheimer’s therapeutics, Nat. Med., 17, 1060, 10.1038/nm.2460 · DOI · Paper page
  75. Selwood, 2009, Gene expression profile of the PDAPP mouse model for Alzheimer’s disease with and without apolipoprotein E, Neurobiol. Aging, 30, 574, 10.1016/j.neurobiolaging.2007.08.006 · DOI
  76. Shen, 2001, Complement activation by neurofibrillary tangles in Alzheimer’s disease, Neurosci. Lett., 305, 165, 10.1016/S0304-3940(01)01842-0 · DOI · Paper page
  77. Snyder, 1998, Expression of VGF mRNA in the adult rat central nervous system, J. Comp. Neurol., 394, 91, 10.1002/(SICI)1096-9861(19980427)394:191::AID-CNE73.3.CO;2-B · DOI
  78. Stein, 2002, Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways, J. Neurosci., 22, 7380, 10.1523/JNEUROSCI.22-17-07380.2002 · DOI
  79. Stover, 2012, Age-related changes in visual acuity, learning and memory in the APPswe/PS1dE9 mouse model of Alzheimer’s disease, Behav. Brain Res., 231, 75, 10.1016/j.bbr.2012.02.044 · DOI
  80. Südhof, 1990, The structure of the human synapsin I gene and protein, J. Biol. Chem., 265, 7849, 10.1016/S0021-9258(19)39008-8 · DOI
  81. Sultan, 2008, A global view of gene activity and alternative splicing by deep sequencing of the human transcriptome, Science, 321, 956, 10.1126/science.1160342 · DOI · Paper page
  82. Sutherland, 2011, Understanding the pathogenesis of Alzheimer’s disease: will RNA-Seq realize the promise of transcriptomics?, J. Neurochem., 116, 937, 10.1111/j.1471-4159.2010.07157.x · DOI
  83. Takemura, 1996, mRNA expression of KIF1A, KIF1B, KIF2, KIF3A, KIF3B, KIF4, KIF5, and cytoplasmic dynein during axonal regeneration, J. Neurosci., 16, 31, 10.1523/JNEUROSCI.16-01-00031.1996 · DOI
  84. Tan, 2003, Cdk5 is essential for synaptic vesicle endocytosis, Nat. Cell Biol., 5, 701, 10.1038/ncb1020 · DOI
  85. Thakker-Varia, 2009, Neuropeptides in depression: role of VGF, Behav. Brain Res., 197, 262, 10.1016/j.bbr.2008.10.006 · DOI
  86. Twine, 2011, Whole transcriptome sequencing reveals gene expression and splicing differences in brain regions affected by Alzheimer’s disease, PLoS ONE, 6, e16266, 10.1371/journal.pone.0016266 · DOI
  87. Upadhaya, 2013, The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice, Acta Neuropathol. Commun., 1, 77, 10.1186/2051-5960-1-77 · DOI
  88. van Bakel, 2010, Most “dark matter” transcripts are associated with known genes, PLoS Biol., 8, e1000371, 10.1371/journal.pbio.1000371 · DOI
  89. van den Pol, 1994, VGF expression in the brain, J. Comp. Neurol., 347, 455, 10.1002/cne.903470311 · DOI
  90. Verwer, 2007, Mature astrocytes in the adult human neocortex express the early neuronal marker doublecortin, Brain, 130, 3321, 10.1093/brain/awm264 · DOI · Paper page
  91. Vogel, 2012, Insights into the regulation of protein abundance from proteomic and transcriptomic analyses, Nat. Rev. Genet., 13, 227, 10.1038/nrg3185 · DOI · Paper page
  92. Wang, 2012, Cathepsin B degrades amyloid-β in mice expressing wild-type human amyloid precursor protein, J. Biol. Chem., 287, 39834, 10.1074/jbc.M112.371641 · DOI
  93. Wang, 2009, RNA-Seq: a revolutionary tool for transcriptomics, Nat. Rev. Genet., 10, 57, 10.1038/nrg2484 · DOI · Paper page
  94. Wirths, 2012, Intraneuronal Aβ accumulation and neurodegeneration: lessons from transgenic models, Life Sci., 91, 1148, 10.1016/j.lfs.2012.02.001 · DOI
  95. Wirths, 2004, A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide – the first step of a fatal cascade, J. Neurochem., 91, 513, 10.1111/j.1471-4159.2004.02737.x · DOI
  96. Wirz, 2013, Cortical beta amyloid protein triggers an immune response, but no synaptic changes in the APPswe/PS1dE9 Alzheimer’s disease mouse model, Neurobiol. Aging, 34, 1328, 10.1016/j.neurobiolaging.2012.11.008 · DOI · Paper page
  97. Wittnam, 2012, Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease, J. Biol. Chem., 287, 8154, 10.1074/jbc.M111.308601 · DOI
  98. Wu, 2006, Comparative analysis of cortical gene expression in mouse models of Alzheimer’s disease, Neurobiol. Aging, 27, 377, 10.1016/j.neurobiolaging.2005.02.010 · DOI
  99. Yahata, 2011, Anti-Aβ drug screening platform using human iPS cell-derived neurons for the treatment of Alzheimer’s disease, PLoS ONE, 6, e25788, 10.1371/journal.pone.0025788 · DOI
  100. Yu, 2012, The role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapy, Mol. Neurobiol., 45, 314, 10.1007/s12035-012-8237-1 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Bouter, Y., Kacprowski, T., Weissmann, R., Dietrich, K., Borgers, H., Brauß, A., Sperling, C., Wirths, O., Albrecht, M., Jensen, L. R., Kuss, A. W., & Bayer, T. A.
Venue
Frontiers in Aging Neuroscience
Publisher
Frontiers Media SA
Published
2014-04-16
Volume
6
ISSN
1663-4365
DOI
10.3389/fnagi.2014.00075
PMC
PMC3997018
Cited by
76
References
20

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review